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Abstract: This study aimed to develop bone implant as either deliver ciprofloxacin to the bone or regenerate bone defects. 
The effect of the composite composition ratio (Bovine Hydroxyapatite-Chitosan) on the physicochemical characteristics of 
Bovine Hydroxyapatite-Chitosan-ciprofloxacin implant were evaluated in this study. Ciprofloxacin implants were prepared 
using four different compositions of composite (Bovine Hydroxyapatite-Chitosan) 20:80; 30:70; 40:60; and 70:30. The 
amount of ciprofloxacin in each implant was 10 %. The powder mixture  was then pressed into pellets. The implants were 
evaluated by various parameters such as porosity, density, water absorption capacity, swelling ratio, disintegration test, 
compression force, drug assay, and in vitro drug release. Characterization of the implants was conducted using Fourier 
Transform Infrared (FT-IR), Scanning Electron Microscopy (SEM), and X-ray diffraction study. The results obtained from 
this work revealed that the composite composition ratio (Bovine Hydroxyapatite-Chitosan) influenced the differences in 
physical characteristics and the release of ciprofloxacin from Bovine Hydroxyapatite-Chitosan-ciprofloxacin implant. The 
iincreased in the Bovine Hydroxyapatite ratio in composite composition caused enhancement of physical characteristics 
(porosity, density, water absorption capacity, and compressive strength) of the implant. Meanwhile, increase in Bovine 
Hydroxyapatite ratio in implant caused lower release of ciprofloxacin. The best composite composition ratio to produce 
Bovine Hydroxyapatite-Chitosan-ciprofloxacin implant with desired physical characteristics and ciprofloxacin release was 
Bovine Hydroxyapatite-Chitosan (70:30). 
Keywords: Composite, bovine hydroxyapatite, chitosan, ciprofloxacin, bone implant.
1. INTRODUCTION 
 
Bone is a composite like material which consists of 
organic and inorganic components such as collagen 
filaments, nanocrystallites, and hydroxyapatite in an 
orderly arrangement layered over several lengths [1].   
A growing demand for bone implants is observed 
worldwide. Every year, approximately 2 × 10
6
 
patients sustain a bone surgical procedure to repair 
bone defect caused by a disease or a traumatic event. 
A biomaterial that has been widely applied to 
develop bone implant is synthetic hydroxyapatite 
(HA). Synthetic hydroxyapatite is a biocompatible, 
osteoconductive, and osteoinductive [2,3]. However, 
synthetic hydroxyapatite has several limitations such 
as high crystallinity, low porosity, poor mechanical 
properties, the risk of residual solvent, and relatively 
expensive [4]. To surmount these problems, Bovine 
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Hydroxyapatite has been produced as the constituent 
material. Bovine Hydroxyapatite is an organic 
component derived from bovine bones and has 
adsorption ability of active factors like antibiotics, 
hormones, and growth factors [5]. The results from 
in vitro and in vivo studies indicated that the natural 
apatite has better osteoconductive characteristics 
than synthetic hydroxyapatite [6].  
Application of synthetic hydroxyapatite or 
Bovine Hydroxyapatite as a single component to 
produce implant has several problems. Bovine 
Hydroxyapatite produces an implant with rigid 
characteristic and fragile [7]. Bovine Hydroxyapatite 
as single materials to construct an implant can act as 
a carrier for drugs, but the release system of the drug 
is hard to predict. Referable to the nonbiodegradable 
characteristics, these materials do not seem to be 
very suitable in tissue engineering perspective [8]. 
One path to overcome the weakness of 
hydroxyapatite as a single component in the bone 
implant is composite. Composite of polymers and 
ceramics such as Bovine Hydroxyapatite can be 
developed to produce implant with sufficient 
mechanical performance and promote bone 
development [9,10]. The combination of an 
inorganic material and organic material can produce 
an implant with desired characteristics in the bone 
engineering field [11]. 
Various kinds of synthetic and natural polymers 
have been applied as organic materials in composite 
and control drug delivery system in humans [12]. 
Among the natural polymers, chitosan is extensively 
used in the development of scaffolds and tissue-like 
materials which mimic body tissues. Chitosan is a 
natural polymer obtained from crab shell, jellyfish, 
coral, and shrimps [1]. Chitosan molecules built 
from glucosamine and N-acetylglucosamine 
constituent connected through the 1-4 glycosidic 
bonds. Chitosan has similar bioactivity like 
glycosaminoglycans and hyaluronic acid, which 
present in articular cartilage [9]. Chitosan is a natural 
cationic polymer that is biologically renewable, 
biodegradable, biocompatible, nonantigenic, 
nontoxic, and bifunctional. Chitosan is a useful 
material in bone reconstruction application and 
tissue engineering due to its hydrophilic surface, 
biocompatibility with human tissue, biodegradability 
by lysozyme, and the ability to promote cell growth 
[13].  
Morphology and physicochemical characteristics 
of the implant are influenced by composite 
composition ratio. An ideal implant must have a 
porous structure, clear pores, and interconnected 
pores [14]. According to the outcomes of the 
previous survey, it can be concluded that Chitosan-
hydroxyapatite composite produces a macroporous 
interconnected structure that supports human 
osteoblast attachment and proliferation, enhance 
bone mineralization, and extracellular matrix 
impeachment [15]. Moreover, hydroxyapatite-
chitosan composites, which have been loaded with 
the drug can improve tissue regeneration. The drugs 
which are entrapped in the structure of the implant 
will leach out and release in a controlled pattern 
around the implantation sites. This process will 
decrease the postoperative complications incidents 
and encourage tissue regeneration [16]. Nowadays, 
several research groups have developed composites 
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consist of hydroxyapatite-chitosan as a drug delivery 
system in the fields of hard tissue engineering [17].  
The development of chitosan-hydroxyapatite 
composites to control the delivery of the drugs to the 
bone has been researched. Chitosan and 
hydroxyapatite built a porous structure where the 
drug will be entrapped inside the pore. In a study, 
tetracycline hydrochloride has been used as a drug 
model. The concentration of tetracycline was 10 % 
w/w. The hydroxyapatite composition in this 
composite was 20 % and 40 %. The composite ratios 
which have been studied were Chitosan 80 % - 
hydroxyapatite 20 % and Chitosan 60 % - 
hydroxyapatite 40 % [16]. During the initial period, 
approximately 30 % of tetracycline was dissolved in 
the media for 2 h. This period revealed the rapid 
drug release or initial burst of the drug when implant 
contact with the media. Burst effect phenomenon 
caused by the release of the drug which attaches at 
the superficies of the composite. The sustained 
release period took place for 72 h. The outcomes 
from this study indicated that increased 
hydroxyapatite content in scaffolds caused 
decreasing tetracycline hydrochloride release rate 
[16]. 
In other research, hydroxyapatite-Chitosan 
composites have been produced in several ratios by a 
one-step co-precipitation method. The ratio of 
hydroxyapatite-Chitosan composites which have 
been studied were, 15:85; 30:70; and 70:30 [18]. It 
can be reasoned that the optimal concentration of 
Chitosan in bone composites was 15 % to 80 % in 
this study [16,18]. In the present study, ciprofloxacin 
hydrochloride is selected as drug models to 
overcome bone infection. The objective of this 
research was to prepare a bone composite designed 
as an implant using hydroxyapatite-Chitosan 
composite in several ratios (20:80; 30:70; 40:60;  
and 70:30) to control ciprofloxacin release. The 
effect of composite composition ratio (Bovine 
Hydroxyapatite - Chitosan) to the physical 
characteristics and the release of ciprofloxacin from 
Bovine Hydroxyapatite - Chitosan - ciprofloxacin 
implant had been considered. 
2. MATERIALS AND METHODS 
2.1 Materials 
Ciprofloxacin (Shangyu Jingxin Pharmaceutical, 
Shangyu, China, CO., LTD), Chitosan (PT. Biotech 
Indonesia, Cirebon, Indonesia), Bovine 
Hydroxyapatite (Tissue Bank Departement of Dr. 
Soetomo Hospital, Surabaya, Indonesia), Glacial 
acetic acid (p.a) (Merck Millipore
®
, USA), Disodium 
hydrogen phosphate (p.a) (Merck Millipore
®
, USA), 
Potassium hydrogen phosphate (Merck Millipore
®
, 
USA), Sodium Chloride (Merck Millipore
®
, USA) 
and Distilled water. Instruments which were used in 
this study include grinder (Keenwood
®
 AT320A), 
hydraulic tablet press machine and waterbath 
(Memmert
®
 GmbH).  
2.2 Methods 
2.2.1 Preparation of Homogenous Chitosan 
            Powder  
The homogenous chitosan powder was made by 
neutralization of chitosan solution in acetic acid       
(2 %) w/v using 1 M NaOH until neutral condition 
reached (pH = 7). This step produced chitosan gels. 
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In the following step, chitosan gels were dried in tray 
dryer for 24 h in the temperature 40 °C. Dried 
chitosan gels, then were milled using grinder to 
produce homogenous chitosan powder [9].  
2.2.2 Preparation of Bovine Hydroxyapatite-     
Chitosan-Ciprofloxacin Implants 
Ciprofloxacin was dissolved in distilled water, and 
then Bovine Hydroxyapatite was added to this 
solution until produce wet mass like paste. Chitosan 
powder was mixed to the mass like paste. Distilled 
water was poured slowly as a granulating liquid to 
make a wet granule mass [11]. Wet granule mass, 
then was milled using 1 mm sieve and dry in 
temperature 50 °C for 24 h to produce dried 
granules. A composite composition which has been 
applied in this work can be viewed in Table 1. Dried 
granules were weighed 100 mg, and compressed 
using 2 t compression pressure using tablet press 
machine. 
           Table 1. Composite composition (Bovine Hydroxyapatite-Chitosan) to produce an implant 
Formulation 
code 
Composite 
composition 
(Bovine 
Hydroxyapatite-
chitosan) ratio 
Ciprofloxacin 
(gram) 
Bovine 
Hydroxyapatite 
(gram) 
 Chitosan 
(gram) 
 
F1 20:80 0.011 0.0178  0.0712  
F2 30:70 0.011 0.0267  0.0623  
F3 40:60 0.011 0.0356  0.0534  
F4 70:30 0.011 0.0622  0.0268  
2.3 Evaluation of implants 
2.3.1  Density and Porosity Test  
Density and porosity test was conducted to predict 
the compactness of the implant. Moreover, this test 
was also conducted to analyze the porosity structure 
of the implant. The density of the implant was 
calculated as in Equation (1) [19, 20].  
                  
              
V
Wi
Density      (1)  
      
Wi is the implant weights  
 V is the implant volume 
Porosity test was evaluated the different weight 
of the implant before and after immersing in 5 mL of 
water for 1 min. Water penetrates the inner structure 
of the implant, so as the weight of the implant after 
immersion was higher than the initial weight. The 
porousness of the implant was calculated as in 
Equation (2). 
100 × 
Wi
– Wi Ww
Porosity                (2)  
  
 Ww is the implant weights after the immersion 
process, 
 Wi is the implant weights before the immersion 
process 
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2.3.2  Swelling and Water Uptake Test  
The swelling ratio and water absorption capacity of 
the implant was found by computing the difference 
in weight of the implant before and after immersing 
in 5 mL phosphate buffer saline (PBS) pH 7.4 at 
temperature 37 °C ± 0.5 °C. The swelling ratio and 
water absorption capacity of the implant was 
analyzed utilizing the Equation (3) and the    
Equation (4) [19, 20].  
 
100 × 
Wi
– Wi Ww
ratio Swelling     (3) 
100 × 
Wi
– Wi Ww
capacity  absorptionWater    (4) 
 Wi is the weight of implant before immersing 
 Ww is the weight of the implant after immersing 
2.3.3  Disintegration Test 
The implants were immersed at 5 mL phosphate 
buffer saline, pH 7.4 at 37 °C ± 0.5 °C. The 
observation was directed to see the switching of the 
implant morphology during the water penetration 
process and erosion [21,22]. The time which was 
taken of the implant to disintegrate into small 
granules or particles is determined as disintegration 
time. 
2.3.4  Hardness testing 
Autograph E-10 instrument was used to evaluate the 
hardness of the implant. The implant was put in a 
compression machine; then the implant was pressed 
by 5 mm min
–1
. The hardness of the implant 
indicated the ability of the implant to support bone 
growth [21].  
2.3.5  Drug content 
In a mortar, one implant was crushed in a mortar. 
After the crushing process, the implant was 
transferred in Erlenmeyer and diluted with 25 mL 
Hydrochloric acid 0.1 N. In the next step; this 
mixture was sonicated for 30 min, then hushed up 
for 24 h in room temperature. Following day, the 
solution was transferred into a 100.0 mL volumetric 
flask and diluted using phosphate buffer saline 
(PBS) pH 7.4. The aliquot then was filtered using the 
Whatman filter paper (0.45 mm diameter). Filtrate  
(1 mL) was pipette and exchanged into 25 mL 
volumetric flasks, then applied to the volumetric 
flasks up to 25 mL of phosphate buffer saline (PBS) 
pH 7.4. This solution then analyzed by 
spectrophotometer UV-Vis to obtain ciprofloxacin 
HCl content in each implant [23,24]. 
2.3.6  In-vitro Drug Release Study  
The drug release from the implant was evaluated by 
vial method using 5 mL of release media. The media 
was phosphate buffer saline (PBS) pH 7.4 and 
incubated in a water bath at 37 °C ± 0.5 °C. At 
predetermined time intervals for 5 d, 1 mL of the 
aliquots were pipetted, then 1 mL of fresh buffer 
transferred into the vial to replace the aliquot. The 
aliquot then prepared by filtrating into the Millipore 
membrane (ø = 0.45 μm) and dilute using phosphate 
buffer saline (PBS) pH 7.4. The amount of 
ciprofloxacin which releases at a predetermined 
interval to the media was analyzed using a UV 
spectrophotometer [15,25]. 
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2.3.7  Data Analysis 
One-way Analysis of Variance (ANOVA) has been 
used to analyze the results of the physicochemical 
evaluation. The physicochemical evaluations which 
are analysed consist of density, porosity, swelling 
ratio, water uptake, disintegration time, and hardness 
of the implant. The results of four formulas have 
been tabulated and analysed using One-Way 
Analysis of Variance (ANOVA) with post-hoc 
Tukey HSD (α = 0.05). The data would be 
significant with P-value < 0.05 (P < 0.05). Tukey 
post-hoc test was used to specify those datas 
showing significant differences with each other. 
2.4 Characterization of Implants 
2.4.1 Evaluation of Implant Morphology using 
         Scanning Electron Microscope (SEM) 
Scanning electron microscope study was performed 
to observe the morphology of the implant. The 
samples were coated with gold and fitted to 
aluminum stubs with conductive paint. The pores 
diameter of the implant were analyzed from the SEM 
micrograph. The pore size was evaluated from the 
different section of the implants [26]. 
2.4.2 Fourier Transform Infrared (FT-IR) 
         Spectroscopy 
The implant was crushed and combined with KBr; 
then the implant pressed into a pellet. The sample 
was analyzed in the wave number range (4 000 to 
400) cm
–1
 using FT-IR spectroscopy [26]. 
2.4.3 X-ray Diffraction Pattern 
Crystallographic phases of the implant were 
observed through X-ray diffractometer  using 
monochromatic Cu Kα radiation (40 KV, 30 MA). 
The x-ray diffraction pattern of the implant was 
analyzed in the 2θ scan range 5º to 50º [26]. 
3. RESULTS AND DISCUSSION  
3.1 Preparation of Bovine Hydroxyapatite-
Chitosan Implants using Different 
Composite Composition 
Implants were prepared by the wet granulation 
method. The wet granulation method was taken to 
produce dry granules with homogenous drug 
distribution, spherical shape, good compressibility, 
and free-flowing characteristic. 
 
A B 
Fig. 1. The results of Bovine Hydroxyapatite-chitosan composite, A) slightly yellow granules, B) implants (cylindrical 
pellets) 
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Wet granule mass was made using four different 
compositions of Bovine Hydroxyapatite-chitosan 
(20:80; 30:70; 40:60; and 70:30). Ciprofloxacin (10 
% w/w) were added to the mixture of the composite. 
Wet granule mass first passed through a sieve, and 
then dried using the oven (50 °C) for 24 h. In the last 
phase, slightly yellow granules were obtained. Dry 
granules then compressed using a single punch tablet 
compression machine to produce pellet (4 mm 
diameters).  
3.2 Evaluation of Implants 
3.2.1 Density and Porosity 
The results of density measurement showed that the 
density of Bovine Hydroxyapatite - chitosan - 
ciprofloxacin implant decreases along with the 
decline of Bovine Hydroxyapatite composition in 
formulas. This is due to the decreased of calcium 
ratio in the implant along with the reduction of 
Bovine Hydroxyapatite composition [27]. The 
density of the implants with four different composite 
compositions can be seen in Fig. 2. 
Fig. 2. The density of F1 to F4 
The porosity of the implant, using four different 
composite compositions, can be viewed in Fig. 3. The 
data displayed in Fig. 3 was mean ± SD (n=3). 
Established along with the outcome of the porosity 
test, it could be concluded that the highest porosity 
was shown by F4. Moreover, the low porosity was 
observed by F1.  
The number of macropore size was found to 
increase with decreasing apparent density, 
consequences the number of microstructures was 
limited. This phenomenon demonstrates that the 
significant reduction of porosity was observed in the 
formula with the lowest proportion of Bovine 
Hydroxyapatite.  
   Fig. 3. The porosity of F1 to F4  
3.2.2  Swelling and Water Uptake Study 
The swelling ratio of F1 to F4 are tabulated in Fig. 4. 
The data displayed in Fig. 4 was mean ± SD (n=3). 
There was a significant difference in porosity 
between F1 to F4 (*P < 0.05). F4 had the highest 
swelling ratio because this formula had the highest 
porosity among four formulas that had been 
established.  
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Fig. 4. The Swelling ratio of F1 to F4 
3.2.3  Disintegration Test 
Disintegration test was conducted to the implant for  
5 d. From the results of this study, it can be observed 
that all the formulas showed swelling mechanism 
when contact with phosphate buffer saline (pH 7.40). 
The results of disintegration test have been tabulated 
in Table 2. 
Table 2. The results of disintegration time of implant         
F1 to F4 
Formulation 
code 
Disintegration time  
(minutes) 
F1 10.12 ± 1.02 
F2 9.45 ± 1.11 
F3 7.10 ± 0.41 
F4 5.03 ± 3.12 
 
3.2.4  Hardness 
The hardness of the implants (F1 to F4) is as shown 
in Fig. 5. The data displayed in Fig. 5 was mean ± SD 
(n=3). Based on the outcome of statistical analysis 
using one way ANOVA, it can be concluded that the 
hardness of F4 was significantly different from F1, 
F2, and F3. 
 
 Fig. 5. The hardness of F1 to F4  
 3.2.5 Drug content  
The analysis of ciprofloxacin in the implant was 
conducted using UV spectrophotometer instruments. 
The drug content was analyzed using three-
wavelength methods, and the results are tabulated in 
Table 3. All the implants contain ciprofloxacin 
between 90 % to 100 %.  
Table 3. The results of ciprofloxacin content in implant   
F1 to F4 
3.2.6 In vitro Drug Release Study  
The cumulative amount of drug release from four 
formulations (F1 to F4) is tabulated in Fig. 6. The 
release of ciprofloxacin from the implant was 
compared to the therapeutic level of ciprofloxacin for 
osteomyelitis, regarding the in vitro study. The 
therapeutic level of ciprofloxacin to produce  
Formulation code Drug content (%) 
F1 93.84 ± 1.05 
F2 94.62 ± 2.06 
F3 96.10 ± 0.96 
F4 99.81 ± 3.37 
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                                      Fig. 6. The ciprofloxacin release profile of F1 to F4 
antibacterial activity is > 2 μg mL–1 [29]. However, 
ciprofloxacin concentration higher than 50 μg mL–1 
caused toxicity in chondrocyte cell [30]. In the initial 
period (for 24 h), the release of ciprofloxacin was 
quite high (burst release). F1, F2, and F3 released 
ciprofloxacin more than the therapeutic level            
(2 μg mL–1 to 50 μg mL–1). F4 showed the release of 
ciprofloxacin between therapeutic level, but nearly 
reached the upper limit of the therapeutic level. 
3.3 Characterization of Implants 
3.3.1 Implant Morphology Study using Scanning 
         Electron Microscope (SEM) 
Scanning Electron Microscope (SEM) study was 
directed to examine the morphology of Bovine 
Hydroxyapatite-chitosan-ciprofloxacin implants. 
Morphology of the implants (F1 to F4) is presented in 
Fig. 7.  
3.3.2 Fourier Transformed Infrared Spectroscopy 
         (FT-IR) Study  
The infrared spectroscopy study was conducted to 
analyze the spectrums of Bovine Hydroxyapatite-
chitosan-ciprofloxacin implants with four different 
compositions of composite (F1 to F4). The spectrum 
of the implant was compared to the infrared spectrum 
of ciprofloxacin, Bovine Hydroxyapatite, and 
chitosan. The infrared spectrums are shown in Fig. 8.  
3.3.3 X-ray Diffraction Study  
X-ray diffraction study has been performed to 
evaluate the crystallographic phase of the implants. 
The results of the x-ray diffraction spectrum of the 
implant and the initial component (Bovine 
Hydroxyapatite, chitosan, and ciprofloxacin) is shown 
in Fig. 9. A wide peak at 2θ ≈ 20° was the specific 
peak of chitosan [16]. This peak indicated the 
crystallinity of chitosan. When the composition of 
Bovine Hydroxyapatite increased in the implant, this 
peak became wider and flatter. It can be concluded 
that Bovine Hydroxyapatite decreased the 
crystallinity of chitosan. Bovine Hydroxyapatite 
decreased intermolecular interaction between chitosan 
chains so that the degree of crystallinity fell down 
[15].  
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                                Fig. 7. SEM micrograph of the implants, A): F1 (BHA-chitosan = 20:80), B): F2  
   (BHA-chitosan= 30:70), C): F3 (BHA-chitosan = 40:60), D): F4 (BHA-chitosan = 70:30). 
                                    Fig. 8. The FT-IR spectrum of, (A): Ciprofloxacin; (B): Bovine Hydroxyapatite;  
(C): Chitosan; (D): Formula 1; (E): Formula 2; (F): Formula 3; (G): Formula 4 
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Fig. 9. X-ray diffraction spectrum of (A): Chitosan; (B): 
Formula 1; (C): Formula 2; (D): Formula 3; (E): Formula 
4; (F): Bovine Hydroxyapatite; (G): Ciprofloxacin  
 
 
4. DISCUSSION 
Physichochemical characterization has been 
conducted to the implant including density and 
porosity, swelling and water uptake, disintegration 
time, hardness, drug content, and in-vitro drug 
release.  The results of density evaluation revealed a 
significant difference in density between the implants 
(*P < 0.05). Post hoc Tukey-HSD test indicated that 
the density of F1 was significantly different with F3 
and F4. Moreover, the density of F2 is also 
significantly different with F3 and F4. F3 and F4 
showed no substantial difference in density. These 
results are in line with the previous study which 
uncovered that the Bovine Hydroxyapatite 
concentration did not affect linearly to the density of 
the implant. The microstructure arrangement of 
Bovine Hydroxyapatite and chitosan conducted a 
significant role to influence the density of the implant 
[27].  
Based on this result, it can be seen that Formula 4 
(Bovine Hydroxyapatite: chitosan = 70:30) had the 
highest density. The increase of Bovine 
Hydroxyapatite proportion in the composite was 
observed increase the density of implants. Bovine 
Hydroxyapatite was dispersed in the chitosan polymer 
wall, so that the more compact structure of the 
implant was obtained. This condition caused the pores 
of the implant became smaller. The results from the 
previous study about the nanohydroxyapatite-chitosan 
scaffold, also showed that the addition of Bovine 
Hydroxyapatite in the formula caused the density of 
the implant became higher comparable to pure 
chitosan scaffold [27]. 
The results of the porosity test were statistically 
analyzed using one-way ANOVA. The porosity of the 
implant, using four different composite compositions 
was significantly different (*P < 0.05). Post hoc 
Tukey-HSD test indicated that the porosity of F1 was 
significantly different with F3 and F4  
(*P < 0.05). The porosity of F2 also significantly 
different with F3 and F4 (*P < 0.05), but the porosity 
of F3 and F4 were not different (*P > 0.05). Slightly 
difference in Bovine Hydroxyapatite composition of 
F3 and F4 did not influenced the microstructure 
arrangement of the implant. Increasing the Bovine 
Hydroxyapatite concentration in a composite caused 
the porosity of the implant higher. By the increase of 
Bovine Hydroxyapatite composition in composite, the 
composition of chitosan was reduced. The reduction 
of chitosan composition led the pore wall to become 
more flexible, and the pore became weaker. However, 
the number of pores increased, so that the porosity of 
the implant increased [27].  
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The porosity of the implant controlled the amount 
of water that will penetrate the structure of the 
implant. Interconnected pores which can be observed 
in F4 play an essential role to increase the porosity of 
the implant. This condition caused the amount of 
water which penetrate to the implant was 
comparatively higher to the other formulas so that 
water will expand the structure of implant rapidly [1]. 
The result of water uptake study revealed a significant 
difference of water uptake between F4 and F1 (*P < 
0.05), F4 and F2 (*P < 0.05),F4 and F3 (*P < 0.05). 
Meanwhile, there was no significant difference in 
water uptake between F1, F2, and F3. F4 had the 
highest water uptake compare to the others. This may 
be due to an increase of Bovine Hydroxyapatite 
composition in the implant structure. The increased of 
Bovine Hydroxyapatite composition caused the 
surface of the implant became rougher and the 
structure became more porous [15]. In addition to 
porosity, the microstructure of the matrix also 
determines the ability of water absorption [27]. Water 
absorption capacity related to the ability of the 
implant to absorb body fluid, transport cell nutrient, 
and transport metabolite [27]. 
Disintegration test was conducted to evaluate the 
ability of the implant to have enlarged pore size when 
applicated in body fluid. Enlargement of the pore size 
can facilitate cell attachment and bone tissue growth 
[27]. F4 showed the fastest disintegration rate among 
the four formulas, whereas  F1 showed the slowest 
disintegration time. This is due to the dissolution of 
hydroxyapatite from the matrix was greater in the 
formula which used high hydroxyapatite composition 
[27]. Moreover, high porosity in the structure of the 
implant also promoted water penetration to the 
implant. This condition caused the implant to swell 
quickly. 
Bovine Hydroxyapatite plays a significant role to 
determine the hardness of the implant. An implant, 
which contains higher hydroxyapatite composition, 
had higher mechanical strength. This was due to 
hydrogen bonding and metal coordination between 
chitosan (NH2 group and OH group of chitosan) and 
ion Ca
2+
 of Bovine Hydroxyapatite. Increasing 
concentration of chitosan in Bovine Hydroxyapatite-
chitosan composite caused the hardness of the implant 
to decrease. The higher chitosan composition in 
composite promotes a weakening of interfacial 
interaction between chitosan and Bovine 
Hydroxyapatite [28]. This phenomenon in line with 
the results of this study, F4 which consist of the 
highest proportion of Bovine Hydroxyapatite 
performed the highest mechanical strength          
(97.74 ± 1.30) MPa. The hardness of F4 nearly 
similar to the hardness of cortical bone filler         
(100 MPa to 120 MPa). 
Parameter to evaluate the difference of 
ciprofloxacin release profile among four formulas 
was area under curve (AUC). The area under the 
curve (AUC) of F1 to F4 were analyzed to observe 
the release pattern of ciprofloxacin. There was a 
significant difference in the area under the curve 
between four formulas. Post Hoc test using Tukey-
HSD showed that the value of the area under curve 
form F4 was significantly different compared to F1, 
F2, and F3. The results of in vitro drug release study 
for 5 d indicated that the release of ciprofloxacin from 
F4 was (491.65 ± 17.00)  μg mL–1. It was only 75 % 
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portion of ciprofloxacin released from F4 compare to 
the other formulas.  This condition showed that the 
drug fraction which left behind from F4 higher than 
F1, F2, and F3. The drug fraction attached to the 
chitosan network of hydrogen bond and ionic 
interaction. The drug fraction also can be absorbed 
into a Bovine Hydroxyapatite particle through high 
affinity with calcium ions [16]. Formula 4 can be 
developed in the next study using crosslink agent to 
control the release of ciprofloxacin during range 
therapeutic range for osteomyelitis (4 wk to 6 wk). A 
cross-linking agent like glutaraldehyde, genipin, and 
tripolyphosphate can be added in the formula to 
control the release of ciprofloxacin.  
Characterization study of Bovine Hydroxyapatite-
chitosan-ciprofloxacin implant was conducted to 
evaluate the morphology structure of the implant, 
crystallographic state, and chemical interaction 
between each component.  The implants had a porous 
structure with nanometer pores. Implants consisted of 
open pores canal and interconnected pores. The pores 
were cylindrical and distributed homogeneously in 
the surface of the implants. The results of SEM 
indicated that F1 had crowd structure and large pores. 
The pore wall was thick and cylindrical. The 
increased of Bovine Hydroxyapatite caused the pores 
became smaller, pore wall became thinner, and the 
number of pores became higher. The results of F4 
showed that the implants had a porous structure. 
Bovine Hydroxyapatite was dispersed in chitosan 
matrix. Bovine Hydroxyapatite formed canal with 
smaller pore canal. An implant which had a porous 
structure enhanced cell attachment to the implant 
during the implantation period. This condition caused 
by tissue infiltration in the structure of implants [15].  
Analysis of the change in functional groups of 
Bovine Hydroxyapatite - chitosan - ciprofloxacin 
implants (F1 to F4) was conducted by comparing the 
infrared spectrum of the implants and starting 
material. The infrared spectrum of Bovine 
Hydroxyapatite – chitosan - ciprofloxacin implants 
showed peaks in wavelength 955 cm
–1
 and 635 cm
–1
. 
These peaks occurred because stretching vibration   
P-O from PO4
3
- group and O-H deformation from 
Bovine hydroxyapatite.  
Furthermore, peak in wavelength 3 571.92 cm
–1
 
caused widening modification of N-H group chitosan 
(3 394.48 cm
–1
). This condition showed by F2 and F3, 
but F1 did not show the same characteristics. The 
infrared spectrum analysis could give an information 
about the possibility of interaction. The interaction 
which occurred among the components in formula 
consisted of hydrogen bond and ionic bond. This 
interaction involved (Ca
2+
 dan PO3
3-
) from Bovine 
Hydroxyapatite and NH2 group of chitosan [28]. This 
phenomenon revealed that chitosan also acts as a 
binding site of Bovine Hydroxyapatite in the structure 
of implants. Characteristics peak of ciprofloxacin, 
which indicated more second amine group (-NH)      
(3 529.49 cm
–1
) and OH group (3 377.12 cm
–1
), did 
not observe in implant formulation. This fact 
explained that there were an interaction via hydrogen 
bound between ciprofloxacin and another component 
in the formula. Hydrogen bound was a weak 
interaction, consequence the bond between 
ciprofloxacin and the other components was 
disrupting quickly when this implant contact with 
Karina Citra Rani et al. 
water. Therefore, ciprofloxacin did not lose its 
activity in implant dosage forms and still effective 
after it was released from the implants [29].  
X-ray diffraction study was performed to evaluate 
the crystallinity state of the implants. The specific 
peaks intensity of Bovine Hydroxyapatite became 
higher along with the increased of Bovine 
Hydroxyapatite composition. The diffraction pattern 
of implants indicated that Bovine Hydroxyapatite was 
in unique crystalline phase [30]. Characteristic peaks 
of Bovine Hydroxyapatite in implants decreased 
when compared to pure Bovine Hydroxyapatite. The 
decreased of Bovine Hydroxyapatite crystallinity in 
implants caused by chitosan molecule [31]. Chitosan 
macromolecules inhibited the growth of Bovine 
Hydroxyapatite along c-axis so that the crystallinity 
of Bovine Hydroxyapatite decreased [15]. The 
diffraction peak of implant showed that the system is 
still in crystalline state, however there was a 
decreased of crystal lattice regularity compare to the 
initial components [32]. 
5. CONCLUSIONS 
Composite composition ratio (Bovine Hydroxyapatite 
and chitosan) influenced the porosity, density, 
hardness, swelling index, and in vitro drug release 
from Bovine Hydroxyapatite-chitosan-ciprofloxacin 
implant. Physicochemical evaluation and in vitro drug 
release study revealed that Formula 4 (Bovine 
Hydroxyapatite: chitosan = 70:30) fulfilled the 
requirement of the ideal bone implant. Moreover, the 
release of ciprofloxacin from this formula was lower 
compared to the other formulas. But, at the initial 
period this formula still released ciprofloxacin higher 
than the therapeutic level of ciprofloxacin in 
osteomyelitis which has been declared from in vitro 
drug release study. 
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